EUnetHTA Joint Action 3 (2016-20) JA3-WP4
2017 - Web Page

Please click on the link(s) below to access the published assessment(s). When there is no link available, the assessment is still ongoing.

Project IDTitle1st AuthorsCo-AuthorsDedicated Reviewers
Other Technologies
OTCA01Wearable cardioverter-defibrillator (WCD) therapy
in primary and secondary prevention of sudden cardiac arrest in patients at risk
LBI-HTAAAZIQWIG, AVALIA-T
OTCA02Antibacterial-coated sutures versus non-antibacterial-coated sutures for the prevention of abdominal, superficial and deep, surgical site infection (SSI)AAZNSPHMPDBSUKL, NIPN/OGYEI,
VASPVT, SNHTA, IQWIG
OTCA03Screening of fetal aneuploidies whereby non-invasive prenatal test (NIPT)Avalia-tRER

MIDT, SNHTA, NIPN, IQWIG


Observer: EOPYY

OTCA04Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancerZINKCELBI-HTA, HAS
OTCA05Repetitive transcranial magnetic stimulation for treatment-resistant major depressionLBI-HTAOstebaKCE, FUNCANIS
OTCA06Transcatheter aortic valve implantation (TAVI) in patients at intermediate surgicial riskAGENASNIPHNOSNHTA, OCSC, HIQA, KCE, REGIONE VENETO
OTCA07Relative effectiveness assessment of Femtosecond laser-assisted cataract surgery (FLACS) compared to standard ultrasound phacoemulsification cataract surgeryRERGOG, HAS

KCE, Osteba, SECS/FUNCANIS and AQUAS

Observer: VASPVT

Pharmaceutical technologies
PTJA01Midostaurin for the indication of Acute Myeloid LeukaemiaFIMEANOMA

TLV, ZIN, HAS, NICE, AEMPS

Information retrieval: IQWIG

Observer: SUKL, SU, EOPPY, SESCS

PTJA02Regorafenib (Stivarga©) indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib treatmentHASINFARMED

AAZ, SNHTA, FIMEA, LBI, NIPN, AETSA

Observer: EOF, EKAPTY

PTJA03Alecensa as monotherapy is indicated for the first-line treatment of adult patients with ALK+ advanced NSCLCTLVHVB, AAZ

NICE, Regione Veneto, Uniba, AETSA, NIPN

Observer: MOH MALTA

Abbreviations: OT-other technologies, PT-pharmaceutical technologies, CA-collaborative assessment, JA-joint assessment